A practical reference on ICP-MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-15. Anything still debated is marked as such rather than presented as settled.
Analytical verification commonly relies on high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Spectroscopic methods such as UV-visible absorption and electron paramagnetic resonance can probe the metal centre itself, since the d9 configuration of copper(II) produces characteristic signals. Elemental analysis or plasma-based techniques quantify copper content. Because each method reports a different aspect of the same sample, purity figures are most meaningful when the technique and its detection wavelength are stated alongside the value.
Stability of the complex in solution depends on pH, temperature, and the presence of competing ligands. It is generally described as more resistant to breakdown than the metal-free chain, since coordination reduces susceptibility to enzymatic attack. Oxidation and hydrolysis can nevertheless proceed over time in aqueous media. Storage guidance in laboratory settings commonly involves refrigeration, protection from light, and avoidance of strongly alkaline conditions. Published data on long-term behaviour vary considerably and depend on the specific matrix.
Handling practices for the solid material emphasise low temperature and dryness. The lyophilised or powdered form is typically kept at refrigerator or freezer temperatures together with a desiccant. Working solutions are often prepared fresh, because repeated freeze-thaw cycles and extended storage may alter the complex. Glass or inert plastic containers are preferred over materials that could leach metal ions into the preparation. Such practices follow general peptide conventions rather than substance-specific regulations.
Published work on GHK-Cu is dominated by in vitro experiments and small animal studies. Human trials tend to be short and small, with endpoints such as skin appearance rather than clinical outcomes. Review articles often summarize the same underlying laboratory findings, which can make the evidence base look broader than it is. Several basic questions remain open: the concentration of the intact complex in human tissue, the route by which it crosses the skin barrier, and whether effects seen in culture produce measurable changes in people.
Laboratory studies describe GHK-Cu as a source of copper that cells can take up, with reported effects on collagen, elastin, and glycosaminoglycan synthesis in cultured fibroblasts. The peptide also appears in wound-repair research, where it is linked to the activity of matrix metalloproteinases and their inhibitors. These observations come largely from cell and animal models. How directly the complex controls any single pathway in intact human skin remains an open question, and reported effects depend on concentration, vehicle, and exposure time.
Copper takes part in redox chemistry, and the same property that makes it useful in enzymes can generate reactive oxygen species when the ion is loosely bound. GHK chelates copper through imidazole, amino, and amide nitrogen donors, which reduces the amount of free copper in solution. Whether that chelation is protective, neutral, or harmful in a given tissue is not settled. Laboratory assays report both antioxidant and pro-oxidant behavior, depending on the conditions and the readout used.
| Property | Value | Notes |
|---|---|---|
| Appearance | Blue crystalline solid | Colour arises from copper(II) d-d transitions |
| Water solubility | Readily soluble | Extent varies with pH and counterion |
| Typical storage | Minus 20 degrees Celsius, desiccated | Protect from light and moisture |
| Purity method | Reverse-phase HPLC, UV detection | Wavelength typically 214 or 220 nanometres |
| Identity method | Mass spectrometry | Confirms peptide mass and copper content |
The peptide was first isolated from human albumin in 1973 by Loren Pickart, who later described its copper-binding behavior. Early work linked the complex to wound healing and tissue remodeling. Plasma levels of GHK decline with age, a pattern that stimulated interest in topical and supplemental applications. Researchers have reported that the tripeptide influences collagen synthesis, antioxidant defense, and inflammatory signaling in cell and animal models. Human clinical evidence remains limited and often relies on small studies.
Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.
Quality control for GHK-Cu relies on documentation and independent testing rather than a single accepted standard. A certificate of analysis may report peptide purity, copper content, residual solvents, water content, and microbial limits, but the underlying methods and acceptance criteria vary by supplier. Verification can include mass confirmation, amino acid analysis, and comparison with a reference standard when one is available. Open questions include how different copper-binding modes or peptide isomers affect measured activity and whether conventional purity assays capture those differences. Buyers of research-grade material typically need to request raw data rather than rely solely on a summary certificate.
Laboratory characterization of GHK-Cu typically combines separation, spectroscopic, and elemental techniques. Reverse-phase high-performance liquid chromatography is widely used to assess peptide purity, often with ultraviolet detection near the copper-related absorption band or with mass spectrometry for identity confirmation. Because the molecule contains copper, elemental methods such as inductively coupled plasma mass spectrometry or atomic absorption spectroscopy are used to quantify metal content and confirm stoichiometry. No single universal pharmacopeial monograph exists for GHK-Cu. Laboratories therefore validate their own methods, and reported purity values depend on the chosen assay and calibration standards.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence found naturally in human plasma, saliva and urine. Loren Pickart reported the isolation of the free peptide in 1973 while studying factors that influenced the growth of aged liver cells in culture. The peptide was later shown to bind copper(II) with high affinity, and the metal-bound form became the focus of most subsequent research. Its concentration in circulation declines markedly with age, a pattern that is well documented, though the physiological consequences of that decline remain debated.
Solutions of GHK-Cu respond strongly to pH, redox conditions, and the presence of competing chelators such as EDTA. Below roughly pH 4 the copper tends to dissociate, because the amide nitrogen donors become protonated and can no longer coordinate. Strongly alkaline conditions instead favour hydrolysis and precipitation of copper hydroxide. Dissolved oxygen and light accelerate breakdown of the peptide backbone, and the copper released during that process can catalyse further oxidation, so dry, cold, dark storage is the usual recommendation.
Routine characterisation relies on reversed-phase high-performance liquid chromatography for peptide purity, paired with mass spectrometry for identity confirmation. Ultraviolet-visible spectroscopy detects the metal centre through its absorption band in the visible region, and inductively coupled plasma mass spectrometry quantifies total copper so that a metal-to-peptide ratio can be calculated. Amino acid analysis confirms the expected residue composition. Together these techniques establish concentration, identity, and stoichiometry, but none of them directly reports biological activity.
Quality specifications for research material commonly state peptide purity, copper stoichiometry, counter-ion identity, and residual water content. Frequent counter-ions include acetate and trifluoroacetate, which differ in mass and in their effect on solubility and handling. Whether batch-to-batch differences in reported responses trace to these parameters or to assay conditions remains an open question, since published comparisons rarely control for all of them at once. Independent verification therefore normally pairs a purity measurement with an elemental copper measurement on the same lot.
Pharmacometrics is a field of study of the methodology and application of models for disease and pharmacological measurement. It uses mathematical models of biology, pharmacology, disease, and physiology to describe and quantify interactions between xenobiotics and patients (human and non-human), including beneficial effects and adverse effects.
== History == The orexin neuropeptides were discovered in 1998 and the role of the orexin system in the etiology of narcolepsy was identified between 1999 and 2000. Subsequent research further established the role of the orexin system in sleep–wake regulation. Due to the promising potential of orexin system modulation in the treatment of sleep disorders, these findings led to translational efforts to bring orexin receptor modulators to medicine as therapeutic agents. Suvorexant was developed by Merck. It entered clinical development in 2006 and was first described in the medical literature in 2010. The medication was approved by the FDA for the treatment of insomnia in the United States on 13 August 2014. Suvorexant was initially released November 2014 in Japan, then later reached the United States in February 2015, Australia in November 2016, and Canada in November 2018. It was the first orexin receptor antagonist to be introduced for medical use, and was followed by lemborexant in 2019 and daridorexant in 2022. Development of almorexant (ACT-078573) and filorexant (MK-6096) was discontinued, while seltorexant (MIN-202, JNJ-42847922) and vornorexant (ORN-0829, TS-142) are still in clinical trials. Suvorexant marketing exclusivity in the United States was set to expire in January 2023 and patent protection is set to expire in 2029 to 2033.
Mala is a numbing and pungent seasoning derived from Sichuan peppercorn and chili. Most commonly, mala is made into a sauce (麻辣醬 málàjiàng) by simmering it in oil and other spices. Characteristic of Sichuan cuisine, particularly Chongqing cuisine, it has become one of the most popular and synthesized ingredients in Chinese cuisine.
==== Catechol O-methyltransferase (COMT) inhibitors ==== Entacapone (Comtan) – catechol O-methyltransferase (COMT) inhibitor Opicapone (BIA 9-1067; BIA-91067; Ongentys; ONO-2370) – catechol O-methyltransferase (COMT) inhibitor [341] Tolcapone (RO-407592; Tasmar) – catechol O-methyltransferase (COMT) inhibitor [342]
== Further reading == Quesada, Ivan; Tudurí, Eva; Ripoll, Cristina; Nadal, Ángel (2008-10-01). "Physiology of the pancreatic α-cell and glucagon secretion: role in glucose homeostasis and diabetes". Journal of Endocrinology. 199 (1): 5–19. doi:10.1677/JOE-08-0290. ISSN 0022-0795. PMID 18669612.
Sources: en.wikipedia.org
=== Manual === The earliest polarimeters, which date back to the 1830s, required the user to physically rotate one polarizing element (the analyzer) whilst viewing through another static element (the detector). The detector was positioned at the opposite end of a tube containing the optically active sample, and the user used his/her eye to judge the "alignment" when least light was observed. The angle of rotation was then read from a simple fixed to the moving polariser to within a degree or so. Although most manual polarimeters produced today still adopt this basic principle, the many developments applied to the original opto-mechanical design over the years have significantly improved measurement performance. The introduction of a half-wave plate increased "distinction sensitivity", whilst a precision glass scale with vernier drum facilitated the final reading to within ca. ±0.05º. Most modern manual polarimeters also incorporate a long-life yellow LED in place of the more costly sodium arc lamp as a light source.
==== Before birth ==== Mammary gland development is characterized by the unique process by which the epithelium invades the stroma. The development of the mammary gland occurs mainly after birth. During puberty, tubule formation is coupled with branching morphogenesis which establishes the basic arboreal network of ducts emanating from the nipple. Developmentally, mammary gland epithelium is constantly produced and maintained by rare epithelial cells, dubbed as mammary progenitors which are ultimately thought to be derived from tissue-resident stem cells. Embryonic mammary gland development can be divided into a series of specific stages. Initially, the formation of the milk lines that run between the fore and hind limbs bilaterally on each side of the midline occurs around embryonic day 10.5 (E10.5). The second stage occurs at E11.5 when placode formation begins along the mammary milk line. This will eventually give rise to the nipple. Lastly, the third stage occurs at E12.5 and involves the invagination of cells within the placode into the mesenchyme, leading to a mammary anlage (biology). The primitive (stem) cells are detected in the embryo and their numbers increase steadily during development.
Periodization refers to the organization of training into sequential phases and cyclical periods, and the change in training over time. The simplest strength training periodization involves keeping a fixed schedule of sets and reps (e.g. 2 sets of 12 reps of bicep curls every 2 days), and steadily increasing the intensity on a weekly basis. This is conceptually a parallel model, as several exercises are done each day and thus multiple muscles are developed simultaneously. It is also sometimes called linear periodization, but this designation is considered a misnomer. Sequential or block periodization concentrates training into periods ("blocks"). For example, for athletes, performance can be optimized for specific events based on the competition schedule. An annual training plan may be divided hierarchically into several levels, from training phases down to individual sessions. Traditional periodization can be viewed as repeating one weekly block over and over. Block periodization has the advantage of focusing on specific motor abilities and muscle groups. Because only a few abilities are worked on at a time, the effects of fatigue are minimized. With careful goal selection and ordering, there may be synergistic effects. A traditional block consists of high-volume, low-intensity exercises, transitioning to low-volume, high-intensity exercises. However, to maximize progress to specific goals, individual programs may require different manipulations, such as decreasing the intensity and increasing volume.
=== Economic and fiscal policy === Since improving the economy of Togo, he has mobilized 12 billion 860 million CFA francs in order for construction of National No. 2. He also reconstructed the nations infrastructure by progressing steps with the Togblécopé and Amakpapé bridges being completed, which is why he had an agenda to develop the country in where he announced in Belgium.
Sources: en.wikipedia.org
The main foreign policy goal of Franz Joseph had been the unification of Germany under the House of Habsburg. This was justified on grounds of precedence; from 1452 to the end of the Holy Roman Empire in 1806, with only one brief period of interruption under the House of Wittelsbach, the Habsburgs had generally held the German crown. However, Franz Joseph's desire to retain the non-German territories of the Habsburg Austrian Empire in the event of German unification proved problematic. Two factions quickly developed: a party of German intellectuals favouring a Greater Germany (Großdeutschland) under the House of Habsburg; the other favouring a Lesser Germany (Kleindeutschland). The Greater Germans favoured the inclusion of Austria in a new all-German state on the grounds that Austria had always been a part of Germanic empires, that it was the leading power of the German Confederation, and that it would be absurd to exclude eight million Austrian Germans from an all-German nation state. The champions of a lesser Germany argued against the inclusion of Austria on the grounds that it was a multi-nation state, not a German one, and that its inclusion would bring millions of non-Germans into the German nation state. If Greater Germany were to prevail, the crown would necessarily have to go to Franz Joseph, who had no desire to cede it in the first place to anyone else.
Katherine J. Franz (born 1972) is an American chemist. She is the chair of the department of chemistry at Duke University. She studies metal ion coordination in biological systems and looks to use the insight to manage species such as copper and iron. Franz was awarded the American Chemical Society Award for Encouraging Women into Careers in the Chemical Sciences.
== Ecological status == In 1998, the International Union for Conservation of Nature warned that one of the primary frankincense species, Boswellia sacra, is "near threatened". Frankincense trees are not covered by the Convention on International Trade in Endangered Species of Wild Fauna and Flora, but experts argue that Boswellia species meet the criteria for protection. In a 2006 study, an ecologist at Wageningen University & Research claimed that, by the late-1990s, Boswellia papyrifera trees in Eritrea were becoming hard to find. In 2019, a new paper predicted a 50% reduction in Boswellia papyrifera within the next two decades. This species, found mainly in Ethiopia, Eritrea, and Sudan, accounts for about two-thirds of global frankincense production. The paper warns that all Boswellia species are threatened by habitat loss and overexploitation. Most Boswellia grow in harsh, arid regions beset by poverty and conflict. Harvesting and selling the tree's resin is one of the few sources of income for the inhabitants, resulting in overtapping.
In summary, impaired N-terminal processing of proIAPP is an important factor initiating amyloid formation and β-cell death. These amyloid deposits are pathological characteristics of the pancreas in Type 2 diabetes. However, it is still unclear as to whether amyloid formation is involved in or merely a consequence of type 2 diabetes. Nevertheless, it is clear that amyloid formation reduces working β-cells in patients with Type 2 diabetes. This suggests that repairing proIAPP processing may help to prevent β-cell death, thereby offering hope as a potential therapeutic approach for Type 2 diabetes. Amyloid deposits deriving from islet amyloid polypeptide (IAPP, or amylin) are commonly found in pancreatic islets of patients suffering diabetes mellitus type 2, or containing an insulinoma cancer. While the association of amylin with the development of type 2 diabetes has been known for some time, its direct role as the cause has been harder to establish. Some studies suggest that amylin, like the related beta-amyloid (Abeta) associated with Alzheimer's disease, can induce apoptotic cell-death in insulin-producing beta cells, an effect that may be relevant to the development of type 2 diabetes. A 2008 study reported a synergistic effect for weight loss with leptin and amylin coadministration in diet-induced obese rats by restoring hypothalamic sensitivity to leptin.
The metabolites of LSD include 2-oxo-3-hydroxy-LSD (O-H-LSD), 2-oxo-LSD, lysergic acid ethylamide (LAE), lysergic acid ethyl-2-hydroxyethylamide (LEO), nor-LSD, 13-hydroxy-LSD, 14-hydroxy-LSD, and the glucuronide conjugates of the 13- and 14-hydroxylated metabolites, among other possible metabolites. The major metabolite of LSD is O-H-LSD. Levels of O-H-LSD in urine have been found to be 4 to 40 times higher than those of LSD, indicating extensive metabolism of LSD into this compound. It is formed by cytochrome P450 enzymes, although the specific enzymes involved are unknown, and O-H-LSD's potential pharmacology is little-studied. However, it was found to have profoundly reduced activity at the serotonin 5-HT2 receptors relative to LSD in vitro. Little is known about the specific enzymes responsible for the formation of LSD metabolites. LSD is not metabolized by monoamine oxidase (MAO) enzymes.
Sources: en.wikipedia.org
Reverse-phase high-performance liquid chromatography with ultraviolet detection is the most common approach. Purity is expressed as a share of total peak area at a specified wavelength. Mass spectrometry is then used to confirm molecular identity.
Solid material is often held at refrigerator or freezer temperatures, typically between minus 20 and 4 degrees Celsius. Desiccation limits moisture uptake. Solution stability is generally shorter and varies with pH and buffer composition.
Electron paramagnetic resonance is suited to copper(II) because of its unpaired electron. UV-visible spectroscopy reveals ligand-to-metal charge transfer bands. Both methods report on coordination rather than on peptide purity.
It is not approved as a pharmaceutical in major markets and is used mainly as a cosmetic ingredient and a laboratory reagent. Regulatory status varies by country and by the product category in which it appears. Claims about therapeutic effects should be treated separately from permitted cosmetic labeling.